Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

While GLP-1 medications like Ozempic and Wegovy have garnered significant attention ... affect multiple body systems ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...